Noven Pharmaceuticals. Inc., (Noven) announced today that XELSTRYM™ (dextroamphetamine) transdermal system, CII, the first and only FDA-approved amphetamine patch for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients six years and older, will be available across the U.S. for healthcare professionals to prescribe later in the first quarter of 2023.
| – XELSTRYM, the first and only amphetamine patch will be available by prescription in Q1 2023 – MIAMI and JERSEY CITY, N.J., Jan. 10, 2023 /PRNewswire/ -- Noven Pharmaceuticals, Inc. (Noven), a wholly owned subsidiary of Hisamitsu Pharmaceutical Co., Inc. focusing on the development of transdermal treatments, announced today that XELSTRYM™ (dextroamphetamine) transdermal system, CII, the first and only FDA-approved amphetamine patch for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients six years and older, will be available across the U.S. for healthcare professionals to prescribe later in the first quarter of 2023.1 In anticipation of this, Noven will be publicly presenting XELSTRYM in a branded capacity for the first time at the American Professional Society of ADHD and Related Disorders (APSARD) Conference being held January 13-15 in Orlando, Florida.
As a Platinum Sponsor of the APSARD Conference, Noven is hosting an industry symposium focusing on ADHD in adults, which will be presented by Greg Mattingly, MD, Associate Clinical Professor, Washington University and President Elect of APSARD. “Noven’s involvement to highlight ADHD in adults at this year’s conference strikes a particular chord of excitement as we’ve learned efforts are underway to develop and publish guidelines in 2023 for the diagnosis and treatment of ADHD in adults, which will address this critical need for healthcare providers and patients,” said Naruhito Higo, PhD, Chief Executive Officer of Noven Pharmaceuticals. “And as the availability of XELSTRYM draws near, Noven continues to pursue our mission of advancing ADHD patient care with diligence and passion, and we look forward to continuing collaboration with key stakeholders in ADHD at APSARD and beyond.” In addition to the symposium and the presentation of two posters by the Medical Affairs Team, Noven is honored to sponsor the 2023 APSARD Early Career/Trainee Award, which will be presented during the conference. XELSTRYM was approved by FDA in March 2022. About Attention-Deficit/Hyperactivity Disorder (ADHD) ADHD is one of the most common neurodevelopmental disorders of childhood. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive behaviors (may act without thinking about what the result will be), or be overly active. ADHD can last into adulthood. Some adults have ADHD but have never been diagnosed. The symptoms can cause difficulty at work, at home, or with relationships. Symptoms can become more severe when the demands of adulthood increase and may look different at older ages, for example, hyperactivity may appear as extreme restlessness. About XELSTRYM™ XELSTRYM is the first and only FDA-approved, once-daily amphetamine transdermal patch for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. XELSTRYM should be applied 2 hours before an effect is needed and removed within 9 hours after application. IMPORTANT SAFETY INFORMATION What is XELSTRYM? XELSTRYM is a central nervous system stimulant prescription medicine used for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children 6 years and older. It is not known if XELSTRYM is safe and effective in children younger than 6 years of age. IMPORTANT SAFETY INFORMATION Abuse and dependence: XELSTRYM, other amphetamine-containing medicines, and methylphenidate have a high chance for abuse and can cause physical and psychological dependence. Your healthcare provider (HCP) should check you or your child for signs of abuse and dependence before and during treatment with XELSTRYM.
XELSTRYM is a federally controlled substance (CII) because it contains amphetamine that can be a target for people who abuse prescription medicines or street drugs. Keep XELSTRYM in a safe place to protect it from theft. Never sell or give your XELSTRYM to anyone else because it may cause death or harm to them and it is against the law. Do not use XELSTRYM if you or your child are:
XELSTRYM can cause serious side effects, including:
Your HCP should check you or your child carefully for heart problems before starting treatment with XELSTRYM. Tell your HCP if you or your child have any heart problems, heart defects, high blood pressure, or a family history of these problems. Your HCP should check your or your child’s blood pressure and heart rate regularly during treatment with XELSTRYM. Call your HCP or go to the nearest hospital emergency room right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with XELSTRYM.
Before taking XELSTRYM tell your healthcare provider if you:
What should I avoid while using XELSTRYM?
What are the possible side effects of XELSTRYM?
Please read the Medication Guide and Full Prescribing Information including the Boxed Warning. To report suspected Adverse Reactions, contact Noven at 1-800-455-8070 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. There is a pregnancy registry for women who are exposed to XELSTRYM during pregnancy. The purpose of the registry is to collect information about the health of women exposed to XELSTRYM and their baby. If you or your child becomes pregnant during treatment with XELSTRYM, talk to your HCP about registering with the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or visit online at https://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/othermedications/ About Noven Pharmaceuticals, Inc. Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. Noven’s mission is to develop and offer pharmaceutical products that meaningfully benefit patients around the world, with a commitment to advancing patient care through transdermal drug delivery. Noven is a standalone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., serving as Hisamitsu’s U.S. platform for prescription pharmaceuticals, and helping Hisamitsu bring the benefits of patch therapy to the world. For more information about Noven, visit http://www.noven.com. For information about Hisamitsu, visit https://global.hisamitsu. XEL-5018-16 Contact: References:
SOURCE Noven Pharmaceuticals, Inc. |
View original content to download multimedia:
